{"id":17197,"date":"2023-07-25T09:44:36","date_gmt":"2023-07-25T13:44:36","guid":{"rendered":"https:\/\/www.progeriaresearch.org\/?p=17197"},"modified":"2025-02-15T17:45:18","modified_gmt":"2025-02-15T22:45:18","slug":"nord","status":"publish","type":"post","link":"https:\/\/www.progeriaresearch.org\/de\/2023\/07\/25\/nord\/","title":{"rendered":"PRF-Mitbegr\u00fcnder ist Vordenker bei der Entwicklung von Medikamenten f\u00fcr seltene Krankheiten"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;0px||0px|||&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.16&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_image src=&#8221;https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/07\/Lesliewcomputer.png&#8221; title_text=&#8221;Lesliewcomputer&#8221; _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.17.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||-77px|||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.17.4&#8243; _module_preset=&#8221;default&#8221; min_height=&#8221;414.9px&#8221; custom_margin=&#8221;-88px|auto|-173px|auto||&#8221; custom_padding=&#8221;||45px|||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.17.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Die Mitbegr\u00fcnderin und medizinische Direktorin der PRF, Dr. Leslie Gordon, wurde k\u00fcrzlich zusammen mit ihrem Kollegen Dr. Francis Collins, wissenschaftlicher Berater des Pr\u00e4sidenten der USA und ehemaliger Direktor der National Institutes of Health (NIH), eingeladen, zu einer Lehrvideoserie der National Organization for Rare Disorders (NORD) beizutragen.<\/p>\n<p>Die beiden wurden gebeten, Erkenntnisse aus ihrer Erfahrung in der Progerieforschung weiterzugeben, die bis zur Entwicklung des internationalen Registers der PRF im Jahr 1999 zur\u00fcckreicht. In den beiden folgenden Videos berichten sie \u00fcber Erkenntnisse aus der Entdeckung des Progerie-Gens im Jahr 2003, \u00fcber die Entwicklung der medizinischen und Forschungsdatenbank der PRF, die Naturverlaufsstudie der PRF und schlie\u00dflich \u00fcber die Zulassung von Lonafarnib, der allerersten Behandlung von Progerie, durch die Food and Drug Administration (FDA), um denjenigen, die in der Erforschung seltener Krankheiten und der Interessenvertretung dieser Krankheiten t\u00e4tig sind, m\u00f6gliche Wege zur F\u00f6rderung der Forschung zu seltenen Krankheiten aufzuzeigen.<\/p>\n<p>[\/et_pb_text][et_pb_button button_url=&#8221;https:\/\/learn.rarediseases.org\/courses\/rare-disease-drug-development-series\/&#8221; url_new_window=&#8221;on&#8221; button_text=&#8221;These videos can be accessed HERE for free in NORD\u2019s Rare Disease Drug Development Series.&#8221; admin_label=&#8221;NORD Dr. Leslie Gordon &#038; Dr. Francis Collins&#8221; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; button_text_color=&#8221;#FFFFFF&#8221; button_bg_color=&#8221;#29327A&#8221; button_border_color=&#8221;#8FD2ED&#8221; background_layout=&#8221;dark&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_button][et_pb_text _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><span>Diese komplette Serie ist \u00e4u\u00dferst informativ f\u00fcr jeden, der sich f\u00fcr die Arzneimittelentwicklung f\u00fcr seltene Krankheiten interessiert, und die Interviews mit Dr. Gordon und Dr. Collins finden Sie im Modul \u201eNaturkundestudien\u201c dieser Serie.<\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":"<p>H\u00f6ren Sie, wie PRF-Mitbegr\u00fcnder und medizinischer Direktor Dr. Leslie Gordon zusammen mit ihrem langj\u00e4hrigen Kollegen Dr. Francis Collins f\u00fcr die NORD-Lehrreihe von ihren Erfahrungen bei der Entwicklung von Medikamenten f\u00fcr seltene Krankheiten berichten. <\/p>","protected":false},"author":2,"featured_media":17213,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[2,1],"tags":[],"class_list":["post-17197","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>nord | The Progeria Research Foundation<\/title>\n<meta name=\"description\" content=\"Hear PRF co-founder and Medical Director, Dr. Leslie Gordon, along with long-time colleague Dr. Francis Collins, share their journey in rare disease drug development for NORD educational series.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.progeriaresearch.org\/de\/2023\/07\/25\/nord\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"nord | The Progeria Research Foundation\" \/>\n<meta property=\"og:description\" content=\"Hear PRF co-founder and Medical Director, Dr. Leslie Gordon, along with long-time colleague Dr. Francis Collins, share their journey in rare disease drug development for NORD educational series.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.progeriaresearch.org\/de\/2023\/07\/25\/nord\/\" \/>\n<meta property=\"og:site_name\" content=\"The Progeria Research Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ProgeriaResearch\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-25T13:44:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-15T22:45:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/07\/4LGFCNORD.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"1000\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Karen Betournay\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Progeria\" \/>\n<meta name=\"twitter:site\" content=\"@Progeria\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Karen Betournay\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/\"},\"author\":{\"name\":\"Karen Betournay\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946\"},\"headline\":\"PRF co-founder serves as thought leader in rare disease drug development\",\"datePublished\":\"2023-07-25T13:44:36+00:00\",\"dateModified\":\"2025-02-15T22:45:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/\"},\"wordCount\":435,\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/07\/4LGFCNORD.png\",\"articleSection\":[\"News\",\"Uncategorized\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/\",\"name\":\"nord | The Progeria Research Foundation\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/07\/4LGFCNORD.png\",\"datePublished\":\"2023-07-25T13:44:36+00:00\",\"dateModified\":\"2025-02-15T22:45:18+00:00\",\"description\":\"Hear PRF co-founder and Medical Director, Dr. Leslie Gordon, along with long-time colleague Dr. Francis Collins, share their journey in rare disease drug development for NORD educational series.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/#primaryimage\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/07\/4LGFCNORD.png\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/07\/4LGFCNORD.png\",\"width\":1000,\"height\":1000},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.progeriaresearch.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PRF co-founder serves as thought leader in rare disease drug development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"name\":\"The Progeria Research Foundation\",\"description\":\"For the Children \u2665 For the Cure\",\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\",\"name\":\"The Progeria Research Foundation\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"width\":300,\"height\":86,\"caption\":\"The Progeria Research Foundation\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ProgeriaResearch\/\",\"https:\/\/x.com\/Progeria\",\"https:\/\/www.instagram.com\/progeriaresearch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946\",\"name\":\"Karen Betournay\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"caption\":\"Karen Betournay\"},\"url\":\"https:\/\/www.progeriaresearch.org\/de\/author\/karenb\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"nord | The Progeria Research Foundation","description":"H\u00f6ren Sie, wie PRF-Mitbegr\u00fcnder und medizinischer Direktor Dr. Leslie Gordon zusammen mit ihrem langj\u00e4hrigen Kollegen Dr. Francis Collins f\u00fcr die NORD-Lehrreihe von ihren Erfahrungen bei der Entwicklung von Medikamenten f\u00fcr seltene Krankheiten berichten.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.progeriaresearch.org\/de\/2023\/07\/25\/nord\/","og_locale":"de_DE","og_type":"article","og_title":"nord | The Progeria Research Foundation","og_description":"Hear PRF co-founder and Medical Director, Dr. Leslie Gordon, along with long-time colleague Dr. Francis Collins, share their journey in rare disease drug development for NORD educational series.","og_url":"https:\/\/www.progeriaresearch.org\/de\/2023\/07\/25\/nord\/","og_site_name":"The Progeria Research Foundation","article_publisher":"https:\/\/www.facebook.com\/ProgeriaResearch\/","article_published_time":"2023-07-25T13:44:36+00:00","article_modified_time":"2025-02-15T22:45:18+00:00","og_image":[{"width":1000,"height":1000,"url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/07\/4LGFCNORD.png","type":"image\/png"}],"author":"Karen Betournay","twitter_card":"summary_large_image","twitter_creator":"@Progeria","twitter_site":"@Progeria","twitter_misc":{"Written by":"Karen Betournay","Est. reading time":"2 Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/#article","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/"},"author":{"name":"Karen Betournay","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946"},"headline":"PRF co-founder serves as thought leader in rare disease drug development","datePublished":"2023-07-25T13:44:36+00:00","dateModified":"2025-02-15T22:45:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/"},"wordCount":435,"publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/07\/4LGFCNORD.png","articleSection":["News","Uncategorized"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/","url":"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/","name":"nord | The Progeria Research Foundation","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/#primaryimage"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/07\/4LGFCNORD.png","datePublished":"2023-07-25T13:44:36+00:00","dateModified":"2025-02-15T22:45:18+00:00","description":"H\u00f6ren Sie, wie PRF-Mitbegr\u00fcnder und medizinischer Direktor Dr. Leslie Gordon zusammen mit ihrem langj\u00e4hrigen Kollegen Dr. Francis Collins f\u00fcr die NORD-Lehrreihe von ihren Erfahrungen bei der Entwicklung von Medikamenten f\u00fcr seltene Krankheiten berichten.","breadcrumb":{"@id":"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/#primaryimage","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/07\/4LGFCNORD.png","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/07\/4LGFCNORD.png","width":1000,"height":1000},{"@type":"BreadcrumbList","@id":"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.progeriaresearch.org\/"},{"@type":"ListItem","position":2,"name":"PRF co-founder serves as thought leader in rare disease drug development"}]},{"@type":"WebSite","@id":"https:\/\/www.progeriaresearch.org\/ta\/#website","url":"https:\/\/www.progeriaresearch.org\/ta\/","name":"Die Progeria Research Foundation","description":"F\u00fcr die Kinder \u2665 F\u00fcr die Heilung","publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization","name":"Die Progeria Research Foundation","url":"https:\/\/www.progeriaresearch.org\/ta\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","width":300,"height":86,"caption":"The Progeria Research Foundation"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ProgeriaResearch\/","https:\/\/x.com\/Progeria","https:\/\/www.instagram.com\/progeriaresearch\/"]},{"@type":"Person","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946","name":"Karen Betournay","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","caption":"Karen Betournay"},"url":"https:\/\/www.progeriaresearch.org\/de\/author\/karenb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.progeriaresearch.org\/de\/wp-json\/wp\/v2\/posts\/17197","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.progeriaresearch.org\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.progeriaresearch.org\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/de\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/de\/wp-json\/wp\/v2\/comments?post=17197"}],"version-history":[{"count":0,"href":"https:\/\/www.progeriaresearch.org\/de\/wp-json\/wp\/v2\/posts\/17197\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/de\/wp-json\/wp\/v2\/media\/17213"}],"wp:attachment":[{"href":"https:\/\/www.progeriaresearch.org\/de\/wp-json\/wp\/v2\/media?parent=17197"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/de\/wp-json\/wp\/v2\/categories?post=17197"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/de\/wp-json\/wp\/v2\/tags?post=17197"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}